Klee Justin B., Co-Chief Executive Officer of Amylyx Pharmaceuticals ($AMLX), sold shares on the open market eight times over the last year, totaling $3.1 million. His most recent sale occurred on March 2, 2026. These sales rank 2,646th among 11,678 individual insiders in our database, where the average is $8.6 million across about 6.4 transactions. He made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 5, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | A | Common Stock | 248865 | $0.00 | 3,583,481.0000 | 109,819,569 | 7.46% | 0.23% |
| March 5, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | A | Stock Option (Right to Buy) | 373295 | $0.00 | 373,295.0000 | 109,819,569 | 9999.99% | 0.34% |
| March 2, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 29282 | $14.47 | 3,334,616.0000 | 109,819,569 | 0.87% | 0.03% |
| Feb. 2, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 15500 | $14.69 | 3,363,898.0000 | 109,819,569 | 0.46% | 0.01% |
| Jan. 16, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | M | Common Stock | 2847 | $7.57 | 3,381,393.0000 | 109,819,569 | 0.08% | 0.00% |
| Jan. 15, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 136193 | $13.58 | 3,378,546.0000 | 109,819,569 | 3.87% | 0.12% |
| Jan. 15, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | M | Common Stock | 197153 | $7.57 | 3,514,739.0000 | 109,819,569 | 5.94% | 0.18% |
| Jan. 16, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | M | Stock Option (Right to Buy) | 2847 | $0.00 | 0.0000 | 109,819,569 | 100.00% | 0.00% |
| Jan. 15, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | M | Stock Option (Right to Buy) | 197153 | $0.00 | 2,847.0000 | 109,819,569 | 98.58% | 0.18% |
| Jan. 16, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 1995 | $13.89 | 3,379,398.0000 | 109,819,569 | 0.06% | 0.00% |
| Jan. 6, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 7715 | $11.09 | 3,317,586.0000 | 109,819,569 | 0.23% | 0.01% |
| Sept. 30, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 200 | $15.01 | 3,325,301.0000 | 88,602,468 | 0.01% | 0.00% |
| Sept. 30, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 29775 | $14.37 | 3,325,501.0000 | 88,602,468 | 0.89% | 0.03% |
| March 31, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 21490 | $3.46 | 3,355,276.0000 | 88,602,468 | 0.64% | 0.02% |
| March 6, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | A | Common Stock | 180118 | $0.00 | 3,376,766.0000 | 88,602,468 | 5.63% | 0.20% |
| March 6, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | A | Stock Option (right to buy) | 270177 | $0.00 | 270,177.0000 | 88,602,468 | 9999.99% | 0.30% |
| March 3, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 4595 | $3.15 | 3,196,648.0000 | 88,602,468 | 0.14% | 0.01% |
| Feb. 5, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | M | Stock Option (right to buy) | 36310 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 5, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | M | Common Stock | 36310 | $1.57 | 3,201,243.0000 | 0 | 1.15% | 0.00% |
| Feb. 3, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 11855 | $3.47 | 3,164,933.0000 | 0 | 0.37% | 0.00% |
| Jan. 6, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 7471 | $4.04 | 3,176,788.0000 | 0 | 0.23% | 0.00% |
| Nov. 4, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | M | Stock Option (right to buy) | 63690 | $0.00 | 36,310.0000 | 0 | 63.69% | 0.00% |
| Nov. 4, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | M | Common Stock | 63690 | $1.57 | 3,184,259.0000 | 0 | 2.04% | 0.00% |
| Sept. 30, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 18589 | $3.20 | 3,120,569.0000 | 0 | 0.59% | 0.00% |
| April 16, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | A | Stock Option (right to buy) | 380000 | $0.00 | 380,000.0000 | 0 | 9999.99% | 0.00% |
| April 16, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | A | Common Stock | 179850 | $0.00 | 3,139,158.0000 | 0 | 6.08% | 0.00% |
| March 5, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 4135 | $18.73 | 2,959,308.0000 | 0 | 0.14% | 0.00% |
| Feb. 26, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | A | Stock Option (right to buy) | 190000 | $0.00 | 190,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 26, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | A | Common Stock | 126667 | $0.00 | 2,963,443.0000 | 0 | 4.47% | 0.00% |
| Jan. 9, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 5841 | $16.33 | 2,836,776.0000 | 0 | 0.21% | 0.00% |
| March 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 96555 | $31.84 | 2,796,062.0000 | 0 | 3.34% | 0.00% |
| March 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 3445 | $32.48 | 2,792,617.0000 | 0 | 0.12% | 0.00% |
| March 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | A | Stock Option (right to buy) | 225000 | $0.00 | 225,000.0000 | 0 | 9999.99% | 0.00% |
| March 16, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | A | Common Stock | 50000 | $0.00 | 2,842,617.0000 | 0 | 1.79% | 0.00% |
| Jan. 6, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 1846 | $36.79 | 2,892,617.0000 | 0 | 0.06% | 0.00% |
| Jan. 6, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | Klee Justin B. | Co-Chief Executive Officer | S | Common Stock | 4122 | $36.08 | 2,894,463.0000 | 0 | 0.14% | 0.00% |